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Abstract
Objective The low alpha/beta ratio of prostate cancer sug-
gests that hypofractionated schemes of dose-escalated radio-
therapy should be advantageous. We report our experience
using stereotactic body radiation therapy (SBRT) for the
primary treatment of prostate cancer to assess efficacy and
toxicity.
Methods From 2007 to 2010, 70 patients (51 % low risk,
31 % intermediate risk, and 17 % high risk) with localized
prostate cancer were treated with SBRT using the Cyber-
Knife system. One-third of patients received androgen dep-
rivation therapy. Doses of 37.5 Gy (n029), 36.25 Gy
(n036), and 35 Gy (n05) were administered in five frac-
tions and analyzed as high dose (37.5 Gy) vs. low dose
(36.25 and 35 Gy).
Results At a median 27 and 37 months follow-up, the low
and high dose groups' median PSA nadir to date was 0.3 and
0.2 ng/ml, respectively. The 3-year freedom from biochem-
ical failure (FFBF) was 100 %, 95.0 % and 77.1 % for the
low-, intermediate- and high-risk patients. A dose response
was observed in intermediate- and high-risk patients with
72 % vs. 100 % 3-year FFBF for the low and high dose
groups, respectively (p00.0363). Grade III genitourinary
toxicities included 4 % acute and 3 % late (all high dose).
Potency was preserved in 83 % of hormone naïve patients.
Conclusion CyberKnife dose escalated SBRT for low-,
intermediate- and high-risk prostate cancer exhibits favor-
able efficacy with acceptable toxicity.
Keywords Stereotactic body radiation therapy . Prostate
cancer . Hypofractionation . Alpha/beta ratio . Dose
escalation
Introduction
Technological and radiobiological advances in early-stage
prostate cancer treatment have led to a debate within the
radiation oncology community over the optimal treatment.
Long-term results from prospective [1, 2] and randomized
dose escalation trials [3–5], comparing doses of 74–81 Gy
to doses <70 Gy show dose escalation with conventional
fractionation (1.8–2.0 Gy per fraction) improves freedom
from biochemical failure (FFBF) and disease progression
with acceptable toxicity. However, despite dose escalation,
improvements are needed to consistently achieve the highest
outcomes.
Brenner and Hall [6] suggested hypofractionation for
prostate cancer as an alternative radiation scheme based on
radiobiological modeling from external beam radiation ther-
apy (EBRT) and low-dose rate brachytherapy series. They
estimated that the alpha/beta (α/β) ratio for prostate cancer
was uniquely low at 1.5 Gy as opposed to about 10 Gy for
other cancers. An α/β ratio <2 Gy would be clinically
significant since late-responding normal tissue near the
prostate has an α/β ratio between 2 and 4 Gy. Therefore, a
hypofractionated dose scheme has the potential to produce a
more advantageous therapeutic ratio. The low α/β ratio for
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prostate cancer is supported by Fowler et al. [7], who
suggested that it may be as low or even lower than 1.5 Gy.
Trials designed to assess these estimates showed that mod-
erately hypofractionated doses were superior to convention-
al fractionation with respect to biochemical control and
survival with acceptable levels of toxicity [8–10]. Indeed,
reviews of clinical datasets support a mean α/β ratio <1.5 Gy
[11, 12].
High dose-rate (HDR) brachytherapy has shown excel-
lent hypofractionated monotherapy results [13], however,
limitations on its use include clinical experience, technology
availability and patient participation in an invasive proce-
dure. Stereotactic body radiotherapy (SBRT), typically five
fractions, is also well suited for hypofractionated radiation
delivery. Several recent SBRT publications report promising
clinical efficacy with minimal toxicity, including series with
5 years follow-up [14–22]. Furthermore, possible reduced
cost and patient convenience make SBRT a desirable treat-
ment modality. We report on intermediate-term toxicity and
efficacy of our SBRT experience for early stage prostate
cancer.
Methods
Eighty-three early stage prostate cancer patients received
SBRT at the Philadelphia CyberKnife Center from 2007
through 2010. Patients with ≥12 months of follow-up are
included in this IRB approved retrospective analysis. SBRT
was delivered using the CyberKnife (Accuray Inc., Sunny-
vale, CA) with MultiPlan inverse treatment planning and
motion tracking of internal fiducials. Treatment planning
began with transrectal or transperineal ultrasound-guided
placement of four gold fiducials into the prostate. A CT
scan (1.25-mm slice thickness) was obtained 10–14 days
later to allow inflammation to subside and ensure fiducials
did not migrate. T2 fast echo MRI was obtained and three-
dimensionally registered by fiducials to the CT in the ma-
jority of patients.
The prostate, seminal vesicles, rectum, bladder, penile
bulb, and bowel were contoured (Fig. 1). Urethra contouring
was preferred, but not required. The clinical target volume
(CTV) was the prostate for low-risk patients and the prostate
plus 2-cm seminal vesicle base for four intermediate-risk and
two high-risk patients. All of the other intermediate- and high-
risk patients had a CTV which encompassed the prostate
without the seminal vesicle bases. A total dose of 35, 36.25
or 37.5 Gy, delivered in five fractions, was prescribed to the
planning target volume (PTV) that consisted of the CTV with
a 5-mmmargin in all directions except 3 mm posteriorly. Dose
administered was standard throughout our center, which was
based on published data available at that time. Initially, we
treated patients with 35 Gy, followed by 37.5 Gy, and at the
time of this publication to 36.25 Gy, which began when we
participated in an Accuray Inc study. The dosimetric goal was
to cover at least 95 % of the PTV with the prescribed dose
normalized to the 75–85 % isodose line (dose heterogeneity
17–33 %). Less than 1 cm3 of rectum received 36 Gy, 50 % of
the prescribed dose could not cross the posterior rectal wall,
and <10 cm3 of bladder received 37 Gy. The average CTVand
PTV were 55.0 cm3 (std dev 27.5 cm3) and 95.4 cm3 (std dev
41.3 cm3), respectively.
Orthogonal 120-kV X-ray image pairs were obtained
throughout treatment for use in motion tracking. The real-
time prostate position was locked-on by the relative fiducial
position on the X-rays. For those patients with evenly distrib-
uted fiducials in the prostate quadrants, the prostate’s rotation
was also tracked and corrections were made in real time.
PSA nadir to date is defined as the lowest PSA value
following SBRT. Benign PSA bounce was defined as a PSA
rise of ≥0.2 ng/ml above its previous nadir with subsequent
decline to that nadir or lower. Biochemical failure (BF) was
assessed using the nadir + 2 (Phoenix) definition. Toxicity
was assessed using the Radiation Therapy Oncology Group
criteria; acute toxicity occurred within 3 months and late
toxicity >3 months following treatment. Risk group was
assessed with the AUA system. Unpaired t-tests assessed
statistical significance.
Results
Patient and treatment characteristics
Seventy patients with a median 31 months (range 13–51)
follow-up were analyzed (Table 1) including one patient
Fig. 1 CyberKnife SBRT treatment plan (36.25 Gy × 5 fractions
prescribed to the 81 % isodose line (white) with a 44.75 Gy maximum
dose. Shown are the prostate (43.6 cm3, red) and PTV (77.8 cm3,
orange). A bladder (green) volume of 1.66 cm3 received 37 Gy and
0.4 cm3 of the rectum (yellow) received 36 Gy
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who died from causes other than prostate cancer or treatment
34 months after SBRT. Neoadjuvant androgen deprivation
therapy (ADT) in the form of luteinizing hormone-releasing
hormone agonist was used in 33 % of patients. The use of
ADT was dependent on individual urologist and radiation
oncologist preference, however, the percentage of the
intermediate- and high-risk patients receiving hormones in
the neoadjuvant and monotherapy groups were similar. Se-
lected low-risk patients received ADT to shrink the prostate
before SBRT. Eight patients received ADT for ≥24months, 13
for 6–24 months, and 2 for <6 months. Patients treated with
SBRT plus ADT are termed the “neoadjuvant group” and
those treated with SBRT exclusively the “monotherapy
group.” Patients who received 35 Gy or 36.25 Gy are termed
the “low dose group” and those who received 37.5 Gy the
“high-dose group.” Tumor stage, Gleason score, risk group,
consecutive treatment days and ADT usage were not signifi-
cantly different between dose groups.
Twenty-nine patients (41 %) received 37.5 Gy, 36
patients (51 %) received 36.25 Gy, and five patients (7 %)
received 35 Gy. Most patients received their treatment over
7 days (45 %), with the next highest proportion receiving
treatment over 5 days (17 %), followed by those on treat-
ment for 8 days (12 %). The remainder completed treatment
between 9 and 15 days with one non-compliant patient
receiving his final fraction several weeks later, all due to
poor adherence to their schedule. Treatment was delivered
with an average of 187 (SD043.0) non-coplanar beams. X-
Table 1 Patient and tumor
characteristics All patients High dose Low dose
Number 70 29 41
Dose (n)
35 Gy 5 0 5
36.25 Gy 36 0 36
37.5 Gy 29 29 0
Age (years)
Median (range) 68 (46–88) 67 (46–80) 68 (51–88)
CTV (cm3)
Median (range) 47.5 (19.0–162.2) 49.87 (31.6–162.2) 44.4 (19.0–107.9)
iPSA (ng/ml)
Median (range) 5.6 (1.1–39.4) 5.7 (1.1–29.5) 5.6 (1.6–39.4)
Tumor stage (n/%)
T1b 1 0/0 % 1/2 %
T1c 52 21/73 % 31/77 %
T2a 7 5/17 % 2/4 %
T2b 4 3/10 % 1/2 %
T2c 6 0/0 % 6/15 %
Gleason score (n/%)
5 2 1/3 % 1/2 %
6 39 15/52 % 24/59 %
7 23 10/35 % 13/32 %
8 6 3/10 % 3/7 %
Risk group (n/%)
Low 36/51 % 14/48 % 23/56 %
Intermediate 22/31 % 11/38 % 10/24 %
High 12/17 % 4/14 % 8/20 %
Maximum baseline GU toxicity grade (n/%)
I 36/51 % 16/55 % 20/49 %
II 9/13 % 3/10 % 6/15 %
Treatment groups (n/%)
Monotherapy 47/67 % 20/69 % 27/66 %
Neoadjuvant 23/33 % 9/31 % 14/34 %
Consecutive treatment days (Mon–Fri) (n/%)
Consecutive days 12/17 % 4/14 % 8/20 %
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ray images were taken every three to five beams to track the
prostate’s movement.
PSA response and biochemical control
PSA values began to gradually decline shortly after SBRT.
The low-dose and high-dose groups’ median PSA nadirs to
date were 0.3 and 0.2 ng/ml, respectively (Table 2). Three
patients (4.2 %), all in the low dose group (Table 3), expe-
rienced BF; two were high-risk and one intermediate-risk,
despite the shorter median follow-up in the low-dose group
(27 vs. 37 months). Overall 3-year actuarial FFBF was
94.5 % (Fig. 2a). A dose response was observed for the
intermediate- and high-risk patients (p00.0363) with 3-year
actuarial FFBF rates of 72 % for the low dose group and
100 % for the high dose group (Fig. 2b). Inclusion of low-
risk patients showed a dose response trend (p00.0775).
Three-year FFBF rates were 100 %, 95.0 % and 77.1 %
for the low-, intermediate- and high-risk groups, respective-
ly (p00.0530) (Fig. 2c). Neoadjuvant ADT in the high-,
intermediate, and low-risk groups was used in 58 %,
50 %, and 14 % of patients, respectively.
In the monotherapy group (median follow-up 29 months),
the two patients with BF (one high- and one intermediate-
risk; dose 36.25 Gy) experienced time to biochemical failure
(TTBF) at 24 and 17 months. One had a bone scan sugges-
tive of metastatic spread and received 8 Gy × 3 fractions to
the right ischium. The monotherapy group also includes five
patients (9 %) with a benign PSA bounce at a median time
of 19 months (range 16–20) after SBRT. Of those patients
without BF, the median PSA nadir was 0.4 ng/ml (range 0.05–
2.9 ng/ml). The largest proportion of PSA nadirs were >0.1
but ≤0.5 ng/ml (Table 2). Median PSA at most recent follow-
up in the monotherapy group patients who did not experience
BF (n045) was 0.4 ng/ml.
In the neoadjuvant group, the sole failure occurred
21 months following SBRT with metastasis to the thoracic
spine. This high-risk patient received ADT >24 months and a
SBRT dose of 35 Gy. Subsequently, this patient was treated
with additional ADT, chemotherapy, and palliative radiother-
apy. Ninety-one percent of PSA nadirs were <0.1 ng/ml,
influenced heavily by hormonal effects. No benign PSA
bounces occurred.
Toxicity
Acute genitourinary (GU) toxicity was moderate and rates
were similar in each dose group (Table 4). Acute grade II
GU toxicities were seen in 19 % (n013), of which nine
patients were in the low dose group and 4 were in the high
dose group. Acute grade III GU toxicities were observed in
4 % (n03), of which two patients were in the low dose
group and one patient was in the high dose group. Two of
the three grade III acute GU toxicities were frequency at
least every hour and one was gross hematuria. These tox-
icities resolved within 3 months of treatment. However, one
case of frequency at least every hour reappeared as a late
toxicity. Acute gastrointestinal (GI) toxicity was limited to
4 % grade II toxicity.
Late toxicity rates were acceptable with severe grade III
toxicity occurring in only two patients (Table 4). Late grade
II GU toxicities were observed in 29 % (n020), of which 13
patients were in the low dose group and seven were in the
high dose group. Late grade III GU toxicities were observed
in 3 % (n02), of which both patients were in the high dose
group. One patient with a 162 cm3 CTV (the largest prostate
in our patient sample) had acute grade III frequency that
resolved within 2 weeks of alpha-blocker and prophylactic
antibiotic treatment, but recurred 6 months later. His symp-
toms improved to grade II immediately after trans-urethral
resection of the prostate (TURP) 13 months after SBRT.
Pathology of the resected tissue was negative for tumor.
The second patient with late grade III GU toxicity experi-
enced urinary retention. He had benign prostate hypertrophy
(BPH) and grade II symptoms at baseline. At 14 months
following SBRT, his symptoms progressed to grade III then
completely subsided following laser TURP. Late GI toxicity
was limited to 4 % grade II toxicity. At most recent follow-
up, no patient was experiencing grade III or higher toxicity.
The most severe persistent toxicities are grade II GU (19 %)
and GI (4 %) with no difference by dose group.
Erectile dysfunction (ED) was assessed for the 29 mono-
therapy patients who were potent before SBRT. At last
follow-up, 17 % lost the ability to achieve erections strong
enough for penetration and required ED medication for
intercourse. No monotherapy patient who was potent before
SBRT developed ED refractory to medical treatment.
Table 2 PSA nadir for patients
in the monotherapy group with-
out biochemical failure separat-











Monotherapy, n047 8/17 % 25/53 % 7/15 % 2/4 % 5/11 %
Low, n032 6/19 % 15/47 % 6/19 % 2/6 % 3/9 %
Int, n010 1/10 % 6/60 % 1/10 % 2/20 %
High, n05 1/20 % 4/80 %
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Discussion
The 3-year actuarial FFBF rates of 100 %, 95.0 % and
77.1 % for low-, intermediate- and high-risk groups and
overall toxicity are concordant with published SBRT out-
comes (Table 5). We further analyzed patients separately as
those who received neoadjuvant ADT and those who re-
ceived SBRT monotherapy due to the confounding effect
that hormonal therapy can have on obscuring true PSA
decline and BF rates. While our study lacks the long-term
follow-up essential to make conclusions regarding rates of BF,
it does offer sufficient follow-up to evaluate nadir PSA to date.
Zelefsky et al. [23] showed that 24-month nadir PSAwas
predictive of distant recurrence. They reported that patients
who fail to achieve a nadir PSA <1.5 ng/ml within
24 months have a higher propensity for relapsing disease.
Lamb et al. [24] further support that the nadir PSA is the
strongest prognostic indicator of all early PSA-based indi-
cators with the ability to predict long-term survival. We
regard the low nadir PSA in our series as indicative of a
favorable outcome despite the limited follow-up. For
example, our monotherapy data show 86 % of patients
with >24 months follow-up reached a nadir <1.5 ng/ml
before 24 months post-SBRT. We report the nadir PSA
to date of the high dose group to be less than that of
Table 3 PSA response and tox-







Grade II Grade III
High dose, n029 37 (24–48) 0 0.2 7/24 % 2/7 %
Low dose, n041 27 (13–51) 3 0.43 13/32 % 0
Fig. 2 FFBF for a all patients, b intermediate- and high-risk patients
by dose group and c all patients by risk group
Table 4 Acute and late maximum toxicity assessed by the RTOG
toxicity scale
Grade I Grade II Grade III
Acute toxicity
GU 39/56 % 13/19 % 3/4 %
Low dose 22/54 % 9/22 % 2/5 %
High dose 17/59 % 4/14 % 1/3 %
GI 12/17 % 3/4 % 0 %
Low dose 8/20 % 3/7 %
High dose 4/14 %
Late toxicity
GU 31/44 % 20/29 % 2/3 %
Low dose 17/41 % 13/32 %
High dose 14/48 % 7/24 % 2/7 %
GI 7/10 % 6/9 % 0 %
Low dose 4/10 % 4/10 %
High dose 3/10 % 2/7 %
EDa 8/28 % 5/17 % 0 %
Low dose 4/25 % 3/19 %
High dose 4/31 % 2/15 %
a ED assessed by CTCAE v3
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the low dose group (0.2 vs. 0.3 ng/ml). It is important
to note that the median follow-up for the high dose
group is 10 months greater than the low dose group.
Therefore, the patients receiving high dose had addition-
al time for their PSA to fall.
It is worth commenting on the median PSA at most recent
follow-up, despite the relatively slow-growing nature of
prostate cancer. At a median follow-up of 32 months, King
et al. report a low median PSA at most recent follow-up of
0.5 ng/ml in low-risk patients who did not receive ADT. Our
results are similar in the monotherapy group (low-,
intermediate-, high-risk patients), which have a median
PSA at most recent follow-up of 0.4 ng/ml at a median
follow-up of 29 months. Although the patients have several
more years to experience BF, these PSAvalues have reached
low levels in a short duration, which may be an indication of
favorable long-term control.
Figure 2b represents a dose response in intermediate- and
high-risk groups, which had similar proportion of patients
receiving neoadjuvant ADT in each group (50 % vs. 58 %).
Few other SBRT publications [16, 17] provide outcomes
stratified by intermediate- and high-risk. In the case of
IMRT, Zelefsky et al. report an 8-year FFBF rate of 67 %
for high-risk patients receiving 81 Gy IMRT with conven-
tional fractionation. While this is a longer follow-up than the
current study, it is important to note that the decline in FFBF
between 3 and 8 years was modest (approximately 77 % vs.
67 %), most likely due to the tendency of early failure for
high-risk prostate cancer patients [25]. Thus, the current
report’s observed 77 % 3-year FFBF rate for high-risk
patients suggests SBRT may have a role in the treatment of
these patients. In regard to intermediate-risk patients treated
with SBRT, Katz et al. has presented data with 4-year actuarial
FFBF of 91 % in those with intermediate risk disease treated
with 35–36.25 Gy plus 28 % receiving ADT. The rate of late
grade III GU toxicity was 1.2 % and median PSA at 46 month
follow-up was 0.1 ng/ml [26]. Furthermore, randomized con-
ventionally fractionated dose-escalation trials have shown
dose responses for intermediate- and high-risk patients [4,
27] similar to those observed here, but limited SBRT dose
escalation results exist.
Katz et al. [28] reported comparable efficacy in primarily
low-risk patients treated with 35 and 36.25 Gy. Their results
indicate a trend toward higher late GU toxicity as dose
increases, which is also a trend in our study with respect
to late grade III GU toxicity but not grade II toxicity (Ta-
ble 4). Boike et al. [21] report dose escalation of 45, 47.5
and 50 Gy for low- and intermediate-risk patients using
3-mm PTV margins. At 30 months median follow-up, the
15 patients receiving 45 Gy experienced similar toxicity and
efficacy compared to the other SBRT publications. Our
observed dose escalation benefit for intermediate- and
high-risk patients includes slightly higher late grade III
GU toxicity, but no significant difference in GI toxicity.
One of the patients with late grade III GU toxicity had the
largest prostate volume in the study (3.5 times larger than
the median volume), which may have contributed to the
severity of his toxicity. While Boike et al. do not report a
dose limiting toxicity, their only grade IV event occurred in
their highest dose group — a group which had 12 months
Table 5 SBRT publications for primary treatment of prostate cancer
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30 99 %, 84 %,
100 %







24 97.3 % 0 %/<1 % 19 %
Madsen et
al. 2007
6.7 Gy×5 40 low 41 90 % 4-year 0 %/0 % none
68 J Radiat Oncol (2013) 2:63–70
median follow-up, suggesting this group’s toxicity rate will
likely increase. It is also important to note that our treatment
is delivered with the CyberKnife, which tracks the fiducial
position throughout treatment whereas Boike et al. track
fiducials prior to each treatment, not during delivery. As
dose increases and PTV margin decreases tracking prostate
motion during treatment becomes more important to ensure
nearby critical structure dose is limited and target dose is not
compromised. Nonetheless, their use of a balloon may sub-
stantially limit the movement of the prostate with the risk of
higher doses to the anterior rectum.
In the prospective study by King et al. [18], there was a
significant reduction in the rate of late grade I toxicities in the
subset of patients treated every other day (QOD). There may
be a benefit for QOD vs. daily fractionation, however, this
phenomenon was not well understood in terms of radiobiolo-
gy. At the time when our patients were treated, QOD fractions
were not used. After analyzing radiobiological models with
prominent radiobiologists in late 2008, we have since decided
to incorporate at least a 1-day break between treatments,
which includes some patients in this study.
Toxicities from IMRT to the prostate have been well docu-
mented. Zelefsky et al. [25] report long-term data on late
toxicity using an IMRT dose of 81 Gy given in traditional
fractionation. At a median follow-up of 7 years with 561
patients, 3 % of patients experienced late grade III GU toxicity
(according to the Common Terminology Criteria of Adverse
Events toxicity scale) and 9 % had late grade II GU toxicity
occurring at a median of 14 months after completion of IMRT.
Late GI toxicity manifested in less than 1 % as grade III and
1.5 % as grade II at a median of 13 months after IMRT
completion. Our current study shows the same proportion of
late grade III GU toxicity and similar late GI toxicity. We
roughly compare late toxicity rates despite the difference in
length of follow-up between the studies since their median
time to late toxicity was 14 months. In a study with similar
length of follow-up, Eade et al. report late toxicities in patients
treated with IMRT doses of 74–78 Gy or I-125 brachytherapy.
Their 3-year actuarial risk of acute and late GU toxicities from
IMRT were 1.4 % and 0.5 %, respectively. There were no
acute or late grade III GI toxicities [29].
Reported potency preservation rates for SBRT include
40 % at 35 months [28] and 80–82 % at 1 year [16, 17].
Wiegner and King [30] compared ED rates following SBRT
to other modalities of radiotherapy alone and concluded ED
rates in the proportion of patients receiving SBRT to be
similar to the upper end experienced by those receiving
other types of monotherapy. In the current study, at a median
31 months 83 % of monotherapy patients remained potent.
Importantly, usage of ED medications increases this potency
preservation rate to 100 %. Nevertheless, comparison of
published potency rates is difficult because different metrics
are used and ED medication usage is not uniformly reported.
Conclusions
These results support the growing body of literature indicat-
ing SBRT for prostate cancer is effective and well tolerated
with excellent FFBF, PSA nadirs, and acceptable toxicity.
The potential benefits of dose escalation in intermediate-
and high-risk patients suggest SBRT offers promise for a
treatment that has improved convenience, low toxicity, ex-
cellent clinical outcomes and likely reduced cost. One lim-
itation of our current study is that BF was not confirmed as
local failure by prostate biopsy. This makes it difficult to
draw strong conclusions regarding a dose response. We can
conclude that dose escalation may be beneficial in specific
patient groups, in order to influence future study design.
Prospective trials for prostate cancer studying SBRT regi-
mens with long-term follow-up and prostate biopsies to
confirm local failure in those with BF are needed to confirm
it as an alternative treatment in comparison to IMRT and
radical prostatectomy. There is currently a randomized
phase II SBRT trial (RTOG 0938) accruing favorable-risk
prostate cancer to hypofractionated schedules of 7.25 Gy ×
5 and 4.3 Gy × 12. Decisions regarding the optimal treat-
ment will eventually become clearer when data from the
randomized trial Prostate Advances in Comparative Evi-
dence compares IMRT to SBRT and SBRT to surgery.
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